Karnataka FDA Spurious Drug Racket Crackdown
Analysis based on 26 articles · First reported Sep 12, 2026 · Last updated Sep 24, 2026
The crackdown on counterfeit medicines may negatively impact Pfizer's reputation and sales in India, though the company's proactive cooperation could mitigate long-term damage. The broader pharmaceutical supply chain in India — Karnataka faces increased regulatory scrutiny, potentially affecting smaller distributors and retailers.
The India — Karnataka Food Safety and Drugs Administration (FDA) uncovered a large-scale spurious drug racket following an August 18, 2026 raid at a farmhouse in Kurubarakeranahalli, Bidadi, India — Bengaluru South district. Authorities seized spurious drugs, machinery, and printing materials worth approximately Rs 5.05 crore, including 5,640 vials of CEFIAVIGENT 2.5 Injection and 1,531 vials of HIZLAM Injectables. The operation involved repacking low-cost medicines into new vials and relabelling them as expensive imported medicines, including products resembling Pfizer brands. The FDA cancelled 16 drug licences and suspended eight others, including the licence of Pfizer Ltd's C&F depot in Nelamangala. A Special Investigation Team (SIT) is probing the supply chain, which reportedly reached over 90 hospitals and clinics in India — Bengaluru. Pharmacy owner Veeresh Kumar Jain was arrested, and more than 15 medical representatives are under scrutiny. The alleged kingpin, Prashant, remains absconding. Pfizer stated that patient safety is its top priority and that it has been cooperating with authorities, removing affected batches from the market. Health Minister U. T. Khader vowed action against those involved regardless of status.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard